Company Profile
Exagen Stock Price, News & Analysis
- Ticker:
- XGN
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
6.59 USD (-0.90%)
Close
Last updated: August 6, 2026
116M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, XGN closed down 0.90% at $6.59. No new same-company headline was identified in the current news window.
Company overview
Autoimmune Diagnostics
Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management.
AVISE CTD
AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines multiple biomarkers into an integrated result intended to improve diagnostic confidence. Exagen operates a centralized clinical laboratory and markets its AVISE portfolio primarily to rheumatologists. Revenue is generated through reimbursed testing, supported by payer coverage and physician adoption.
Future catalysts
Exagen is heading into a more important stretch around its latest development priorities. Management's latest framing highlights the next company-specific pipeline update. The stock is likely to react most to whether those milestones keep moving without a reset.
Recent news
- 01
- 02
- 03
- 04
- 05
Exagen Inc. Reports First Quarter 2026 Results
Source: Exagen
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Exagen (XGN)?
Exagen (XGN) most recently closed at 6.59 USD, a -0.90% move versus the previous session.
What is the market cap of Exagen (XGN)?
Exagen currently has a market capitalization of 116M USD on BioPharmSignal.
What does Exagen do?
Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines multiple biomarkers...
On which exchange is XGN stock listed?
Exagen (XGN) is associated with NASDAQ, United States, MedTech.
What is Autoimmune?
Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases.
Which conditions is Exagen targeting with Autoimmune?
Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines multiple biomarkers...
How does Exagen describe recent progress with Autoimmune?
Exagen is heading into a more important stretch around its latest development priorities. Management's latest framing highlights the next company-specific pipeline update. The stock is likely to react most to whether those milestones keep moving without a reset.
What is Diagnostics?
Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases.